Alternative splicing (AS) is an important event that contributes to posttranscriptional gene regulation. This process leads to several mature transcript variants with diverse physiological functions. Indeed, disruption of various aspects of this multistep process, such as cis- or trans- factor alteration, promotes the progression of colorectal cancer. Therefore, targeting some specific processes of AS may be an effective therapeutic strategy for treating cancer. Here, we provide an overview of the AS events related to colorectal cancer based on research done in the past 5 years. We focus on the mechanisms and functions of variant products of AS that are relevant to malignant hallmarks, with an emphasis on variants with clinical significance. In addition, novel strategies for exploiting the therapeutic value of AS events are discussed.

**FACTS**

1. Pre-mRNA alternative splicing events increase the complexity of gene regulation and transcript diversity
2. Variable cis-regulatory elements and alterations in splicing trans-regulatory factors regulate alternative splicing events
3. Aberrant alternative splicing influences colorectal cancer progression by regulating the cell proliferation, invasion, and apoptosis, as well as angiogenesis and drug-resistance
4. Antisense oligonucleotides and small molecule inhibitors are therapeutic agents based on splicing alterations
5. Further studies are needed to enhance the targeting efficiency of antisense oligonucleotides in CRC patients.

**OPEN QUESTIONS**

1. Alternative splicing is an important molecular event contributing to post-transcription regulation. What kinds of abnormal changes in splicing sequence and regulatory factors lead to splicing variant alterations in colorectal cancer?
2. Alterations of alternative splicing result in several products that are carcinogenic. What role do the products play in colorectal cancer?
3. Alternative splicing provides new targets for cancer treatment. Does targeting the multi-steps of alternative splicing provide important clinical value?

**INTRODUCTION**

Alternative splicing (AS) of precursor messenger RNA (pre-mRNA) has been shown to influence physiological and pathological processes. Pre-mRNA splicing was first discovered in 1977, and has now been shown to play important roles in posttranscriptional regulation of gene expression [1]. Notably, AS increases the diversity of transcript variants and proteomic isoforms. A recent analysis of the Encyclopedia of DNA Elements (ENCODe) project 1 (GRCh38, Ensembl79) and data from recent research have revealed that the human genome consists of ~21,306 protein-coding genes [2, 3], but the number of transcript variants and protein isoforms is considerably higher because of AS [4]. Alternative and aberrant pre-mRNA splicing have the potential to act as diagnostic and treatment targets, especially in primary and metastatic tumors [5].

Colorectal cancer (CRC) has been reported to have the third-highest mortality and morbidity rates in the latest epidemic oncology study in the United States. Investigations into the fundamental pathological mechanisms of CRC have revealed that AS events can be exploited to offer more diagnostic and treatment agents for cancer [6]. The first study on AS in CRC revealed that c-Ki-ras (KRAS), a protein-coding gene, mutates at splice acceptor site and produces two transcript variants with...
SPlicing MACHINERY AND ALTERNATIVE SPlicing

A sophisticated spliceosome machinery is responsible for splicing pre-mRNA by recognizing different splice sites. This machinery catalyzes two fundamental transesterification reactions in the nucleus [12]. The process of pre-mRNA splicing is regulated by specific recognition between cis- regulatory elements (pre-mRNA sequence) and trans-regulatory factors (proteins in splicing process). This is followed by cutting and joining of ribonucleotide base sequences [13]. In the review, we discuss the mechanisms by which the spliceosome routinely removes introns and joins exons to generate a mature mRNA and the classical types of AS.

The spliceosome machinery

The core spliceosome comprises small nuclear ribonucleoprotein (snRNP) complexes (U1, U2, U4/U6, and U5 snRNP) that carry functional uridine-rich small nuclear RNAs (U1, U2, U4/U6, and U5 snRNA), respectively [14], together with over 50 intrinsic proteins [15, 16]. It also contains specific extrinsic non-spliceosomal RNA-binding proteins that regulate protein-RNA crosslink sites and splicing, such as the canonical heterogeneous nuclear ribonucleoproteins (hnRNPs) [17], serine-arginine amino acid-rich proteins (SR proteins) [18] and other tissue-specific splicing factors [19]. The intrinsic complexes and regulatory proteins act as trans-regulation factors of RNA splicing.

The cis-regulatory elements consist of direct binding sites and indirect regulatory sites that participate in fundamental and complex steps of pre-mRNA splicing modification (Fig. 1A). Three consensus sequence elements directly bind to trans-regulatory factors and promote the transesterification reactions of splicing, including the 5’ splice site (5’S, also called donor site), branch point sequence (BPS) and 3’ splice site (3’S, also called acceptor site) [20]. Certain cis-regulatory elements that occur in exonic splicing enhancer (ESE), exonic splicing silencer (ESS), intronic splicing enhancer (ISE), and intronic splicing silencer (ISS) sequences are crucial elements in the regulation of splicing [21]. Overall, SR proteins recognize and bind to splicing enhancer elements (ESES and ISES), whereas hnRNP target splicing silencer elements [22].

The main splicing process, which includes several key mechanisms, such as RNA–protein interactions, splicing factors with ESE, ESS, IES, and ISS interactions, RNA–RNA base-pairing interactions, and chromatin-based effects, is accompanied by spliceosome assembly, activity, and disassembly cycle (Fig. 1B) [22]. The initial splicing procedure begins with recognition of the 5’S GU ribonucleotide by U1 snRNP and recognition of the branch point sequence (BPS) by Splicing Factor 1 (SF1) that forms the first spliceosome complex E. The U2 Auxiliary Factor 2 (U2AF2) binds to polypyrimidine tract (Py-tract) or U2 Auxiliary Factor 1 (U2AF1) binds to 3’S [23]. Afterward, U2 snRNP and the preassembled U4/U6/U5 tri-snRNP occupy and then are substituted in turns among splicing process, and final transesterification reactions form a mature mRNA with a lariat (detail illustrated in Fig. 1B) [24–26].

The common types of alternative splicing

Alternative sites that possess similar sequences to the consensus splicing elements are spliced by spliceosome to generate a variety of mature mRNAs because of attenuated affinity between consensus splice site and snRNPs. High-throughput RNA sequencing and analysis revealed that 90–95% of human multi-exon genes produce transcript variants through AS [27]. The common types of AS include cassette exon skipping, intron retention, mutually exclusive exon, alternative 5’S splice site, alternative 3’S splice site, alternative first and last exon (AFE and ALE, respectively), and alternative promoters (Fig. 1C). Moreover, cassette exon skipping and intron retention are predominant in human AS types [5, 28]. Variable AS events not only produce thousands of variants, but also exhibit tissue or pathological specificity, and provide new targets for diagnosis and treatment of cancer [5, 29].

ABERRANT REGULATION OF ALTERNATIVE SPlicing ASSOCIATED WITH CRC

Aberrant AS has resulted in great achievements in CRC treatment with the advancement in sequencing technology, such as a cohort study of 1231 CRC cases with targeting sequencing of 36 putative CRC susceptibility genes, revealed that 8 genes of them generated 36 novel specific protein isoforms due to AS [30]. The dysregulation mechanism can be ascribed to two common aspects: cis-elements and trans-regulation factors (Fig. 2). The reasons for aberrant AS and the generation of corresponding transcript variants in CRC are discussed in the subsequent section.

Variable cis-regulatory elements

The cis-element sequence and structure contribute to the regulation of AS. Generally, the velocity of splicing is dependent on the speed of splicing machineries and nascent pre-mRNA transcription elongation when splicing occurs co-transcriptionally following the translocation of RNA polymerase II (Pol II) [31]. Pre-mRNA sequences carry splicing codes and influence protein function, whereas chromatin structure like histone nail modification and Pol II transcription influence splicing by adjusting the affinity of cis-elements to trans-regulatory factors and speed of transcription [32]. The effect of cis-elements changes on AS can be classified into three categories: single-base substitutions, translocation, and alteration of chromatin or promoters. Additional aberrant cis-regulation mechanisms are listed in Table 1.

Single base substitution. The integrated analyses of DNA and RNA sequences revealed that somatic mutations at donor sites or acceptor sites can increase the potential of aberrant splicing events and new transcript variants [33, 34]. Single base substitution can adequately induce aberrant splicing events in patients with CRC [35], especially when mutations occur at direct splice sites or regulatory elements. A study of 369 patients with Lynch syndrome cohort revealed that ~40% of patients carried the mutL homolog 1 (MLH1) mutation, with the most common type of mutation was direct splice site alterations [36], which was consistent with the findings of computational analyses conducted by Frey [32].

Specific single base mutations could create a new splicing site as a competitor, such as mutations at the acceptor splice site of MSH2 (c.212-1G>A), which induces activation of a new splice site in exon 2 and generates truncated proteins (p.Gly71Valfs*2 and p. Gly71Glufs*7S), is identified in young patients with genetic predisposition to colon cancer [37]. In addition, single base substitution with offering novel splicing sites of other genes was
presented in Table 1, such as BRF1 RNA polymerase III transcription initiation factor subunit (BRF1) germline mutation of c.1459 +2T>C [38], PMS1 homolog 2 (PMS2) mutation of c.2002A>G [39]. Furthermore, loci of the mutations in ESE, ESS, IES, or ISS elements are also key splicing regulators in CRC. The SNPs of ISS sites between exon 4 and 5 in O-GlcNAc transferase (OGT) can increase mRNA intron retention variants by slowing down splicing speed, which induces tumorigenesis [40]. Although numerous studies on germline mutations are associated with AS in CRC, few studies have reported the mechanisms of somatic mutations in patients with CRC clearly.

**Translocation.** Translocation of sequences, including insertion or deletion of a long or short gene fragment, is a primary regulatory mechanism of splicing. These phenomena have been observed in patients with Lynch syndrome, an inherited condition that increases the risk of colon cancer. Single base-pair deletion, MSH2 (c.2635-3delC) lost the ability of the splicing acceptor site promotes an aberrant variant with intron 15 retention, whereas paracentric inversion AluY repeats brings novel splicing donor site and acceptor site at exon 1 and exon 7, and then generates a truncated isoform lacking exon 2-6 [41, 42]. Details of other translocations that are related to splicing in CRC are shown in Table 1, such as germline mutation of 2 base-pair deletions at the splice donor site of MLH1 exon 6 [43] and insertion-deletion (indel) at codon 409 of APC [44].

**Aberrant chromatin and promoters.** Splicing events are influenced by the chromatin features, such as epigenetic modification of DNA methylation and histone acetylation. In HCT 116 cells, inhibition of histone deacetylase (HDAC) that specifically increases...
Fig. 1 Components of the spliceosome machinery and the common types of alternative splicing. The figure shows an outline diagram of spliceosome components and clinical treatment targets with experimental evidence. A The elements that participate in pre-mRNA splicing. The U1, U2, U3, U4, and U5 are small nuclear ribonucleoprotein (snRNP) complexes that directly bind to splicing sites by recognition between snRNAs and pre-mRNA. The 5’ splice site (5’SS), the branch point sequence (BPS) and the 3’ splice site (3’SS) are relatively conserved sequences recognized by snRNPs. The major spliceosome splices introns containing GU at the 5’SS and AG at the 3’SS. The typical sequence of BPS is YNYYRAY (Y: pyrimidine; N: any nucleotide; R: purine; A: adenine). The classical/canonical hnRNPs (Heterogeneous nuclear ribonucleoproteins) and SR proteins (serine/arginine amino acid-rich proteins) regulate splicing by binding to the splicing cis-regulatory elements, including exon splicing enhancer (ESE), exonic splicing silencer (ESS), intronic splicing enhancer (ISE), and intronic splicing silencer (ISS) sequences. B The major splicing process is accompanied by the interaction between cis-elements and trans-factors with spliceosome assembly cycle. The gray box shows the stepwise interaction of the small nuclear ribonucleoprotein (snRNP) particles changes with the removal of an intron from a pre-mRNA. The first step of splicing is trans-elements bind to the conserved sequence of introns, including U1 binding to 5’SS, SF1 binding to BPS and U2AF2 binding to Py-tract and U2AD1 binding to 3’SS, which forms the first spliceosome complex E. Then U2 will replace SF1 and interact with BPS, forming the spliceosome complex A. And U4/5/U6 tri-snRNP substitutes U1, with U5 binding to 5’SS and U6 binding to U2. After that, U4 dissociates from the B complex and some regulatory splicing proteins are recruited, forming the early B act complex (B*). Two steps of transesterification complete splicing progress. U6/U2 catalyzes transesterification reactions by making the BPS ligate to 5’-end of the intron and form a lariat, and the 5’ site is cleaved, resulting in the formation of the lariat. This is followed by a 5’SS-mediated attack on the 3’SS, leading to the removal of the intron lariat and the formation of the spliced RNA product. The proteins are recycled and used in the next splicing process (showed as dotted lines). C Common models of alternative splicing and the corresponding transcript variants. The solid and dashed lines denote different alternative splicing models. Cassette exon skipping: an intervening exon between two other exons can be either included or skipped. Intron retention: an intron remains in the mature mRNA instead of being spliced. Mutually exclusive exon: only one out of two exons (or one group out of two exon groups) is retained with the other one is spliced out. Alternative 5’SS: a potential 5’SS replaces the consensus 5’SS and is joined to 3’SS. Alternative 3’SS: a potential 3’SS replaces the consensus 3’SS and is joined to 5’SS. Alternative first exon: the first exon is replaced by the identical boundaries in the second exon and is exclusive. Alternative last exon: the last exon is substituted by the penultimate with a similar splicing site and exclusive. Alternative promoter: alternative transcription initiation sites also affect the splicing pattern of downstream exons.

Fig. 2 The mechanism of aberrant splicing in colorectal cancer. The diagram shows the classifiable explanation of abnormal splicing in CRC. Splicing occurs co-translationally on nascent RNA, which is attached to chromatin by RNA polymerase II (shown in the left figure). Both alterations of cis-elements and trans-regulatory factors would cause abnormal splicing events and products. New recognized sites are created by mutation of cis-elements like single base substitutions, translocation, and alternative promoters (the first diagram on the right). Alteration of chromatin would influence affinity between splicing factors to splicing sites by conformational change or speed of transcription elongation with changed time of splicing factors loading on cis-elements (the second diagram on the right). In addition, the expression and post-modification of trans-regulatory alter the splicing by infecting recognition between splicing factors and splicing sites. K (lysine) acetyltransferase 2B (KAT2B) occupancy and histone3/4 acetylation nucleosome can increase exon 2 exclusion in myeloid cell leukemia sequence 1 (MCL1) transcript variant [45]. Inhibition of HDAC resulted in hyperacetylation of H3K4me3 nucleosomes and increased the rate of elongation through these regions, which did not leave sufficient time for the loading of SRSF1 onto exon 2. The absence of SRSF1 and other splicing factors at exon 2 resulted in increasing the MCL1 exon 2 exclusion [45]. And the trimethylation of H3K36me3 accelerated transcription elongation and reduced the removal of intron 2 of disheveled segment polarity protein 2 (DVL2) [46]. In addition, different transcriptional initiation sites can alter splicing with additional splicing sequences. The prominent promoter 2 of hepatocyte nuclear factor 4 alpha (HNF4a), rather than promoter1, is transcribed into P2-HNF4a pre-mRNA with extra exon 1D and provides more splicing sites, which results in increased pro-proliferation HNF4a7/8 splice variants [47, 48].

Alterations of splicing trans-regulatory factors
In CRC, alternative splicing can be regulated by trans-regulatory factors in form of mutations, dysregulated expressions or protein-modifications of RNA-binding proteins (RBPs) that occur in spliceosome components and splicing regulators [49, 50]. Alterations that occur in trans-regulatory factors are shown in Table 2.

K (lysine) acetyltransferase 2B (KAT2B) occupancy and histone3/4 acetylation nucleosome can increase exon 2 exclusion in myeloid cell leukemia sequence 1 (MCL1) transcript variant [45]. Inhibition of HDAC resulted in hyperacetylation of H3K4me3 nucleosomes and increased the rate of elongation through these regions, which did not leave sufficient time for the loading of SRSF1 onto exon 2. The absence of SRSF1 and other splicing factors at exon 2 resulted in increasing the MCL1 exon 2 exclusion [45]. And the trimethylation of H3K36me3 accelerated transcription elongation and reduced the removal of intron 2 of disheveled segment polarity protein 2 (DVL2) [46]. In addition, different transcriptional initiation sites can alter splicing with additional splicing sequences. The prominent promoter 2 of hepatocyte nuclear factor 4 alpha (HNF4a), rather than promoter1, is transcribed into P2-HNF4a pre-mRNA with extra exon 1D and provides more splicing sites, which results in increased pro-proliferation HNF4a7/8 splice variants [47, 48].

Alterations of splicing trans-regulatory factors
In CRC, alternative splicing can be regulated by trans-regulatory factors in form of mutations, dysregulated expressions or protein-modifications of RNA-binding proteins (RBPs) that occur in spliceosome components and splicing regulators [49, 50]. Alterations that occur in trans-regulatory factors are shown in Table 2.
Table 1. The aberrant changes of cis element of splicing.

| Gene   | Mutant site | Mutant type          | Splicing mechanism | Splicing alteration                                      | Somatic or germline       | Reference |
|--------|-------------|----------------------|--------------------|---------------------------------------------------------|---------------------------|-----------|
| BRCA2  | c.7802A>G   | Single base substitution | Splice donor site  | Skipping the last four nucleotides of exon 16           | Germline mutation         | [127]     |
| BRF1   | c.1459+2T>C | Single base substitution | Splice donor site  | Skipping of exon 13                                     | Germline mutation         | [38]      |
| DPDY   | c.321+2T>C  | Single base substitution | Splice donor site  | Skipping of exon 4                                      | –                         | [128]     |
| MLH1   | c.543C>T    | Single base substitution | Splice donor site  | Deletion of the last 4 bases of exon 6                  | Germline mutation         | [129]     |
| BRCA2  | c.67+3A>G   | Single base substitution | Splice donor site  | Skipping of exon 2                                      | Germline mutation         | [130]     |
| MSH2   | c.2634+1G>C | Single base substitution | –                  | Skipping of exon 15                                     | Germline mutation         | [131]     |
| PMS2   | c.2002A>G   | Single base substitution | Splice donor site  | 5 bp deletion at the exon 11-12 junction                | Germline mutation         | [39]      |
| TP53   | c.96+1G>A   | Single base substitution | Splice donor site  | Exon 3 skipping                                         | Somatic mutation          | [132]     |
|        | c.782+1G>A  | Single base substitution | Splice donor site  | Intron 7 retention                                      | Somatic mutation          |           |
|        | c.920-2A>G  | Single base substitution | Splice acceptor site | Intron 8 retention or exon 9 skipping                  | Somatic mutation          |           |
|        | c.919+1G>A  | Single base substitution | Splice donor site  | Intron 8 retention or exon 8 skipping                  | Somatic mutation          |           |
|        | c.560-1G>A  | Single base substitution | Splice acceptor site | Intron 5 retention or exon 6 skipping                  | Somatic mutation          |           |
| MSH2   | MSH2 (hg19, chr2: 47 653 051) | Inversion of AluY repeat in intron1,6 | Donor site at exon1, acceptor site at exon7 | Skipping of exon2-6               | Germline mutation         | [41]     |
|        | c.2635-3delC | Single base missing | Acceptor site of exon 16 | Part of intron 15 retention | Germline mutation         | [42]     |
| MLH1   | c.545+4545+5delKA | Deletion of 2 bp in splice donor site | Donor site of exon 6 | Skipping of exon 6                                      | Germline mutation         | [43]     |
| APC    | c.1226+1229delTTTInsAAA | Insertion–deletion at codon 409 | S’ end of exon 9 | Skipping of exon 9                                      | Germline mutation         | [44]     |
| HNF4a  | –           | Alterative promoter   | Different pre-mRNA | Skipping of exon 1                                      | –                         | [47, 48] |
| MCL1   | –           | Histone acetylation   | Increase H3/4 acetylation | Skipping of exon2                                  | –                         | [45]     |
| DVL    | –           | Histone methylation   | Decrease H3K36 methylation | Intron 2 retention                        | –                         | [46]     |
| Trans-regulation factor | Classification | Alteration | Aberrant mechanism | Splicing target | Product change | Splicing effect | Reference |
|------------------------|----------------|------------|-------------------|----------------|----------------|----------------|-----------|
| SRSF1                  | SRs            | Upregulated| Transcription upregulation | DBF4B          | Full-length DBF4B upregulated | DBF4B exon6 inclusion | [54]      |
| SRSF1                  | SRs            | Upregulated| Transcription upregulation | HNRPLL         | HNRPLL-E12A RNA upregulated | HNRPLL with Exon12a skipping | [55]      |
| SRSF3                  | SRs            | Upregulated| –                  | PDCD4          | PDCD4 A5-1 RNA upregulated | Part of exons 2 and 3 skipping | [56]      |
| SRSF3                  | SRs            | Upregulated| Transcription upregulation | PKM            | PKM1/PKM2 upregulated | PKM1(exon 9 inclusion) | [57]      |
| PTBP1                  | hnRNPs         | Upregulated| Transcription upregulation | PKM            | PKM1/PKM2 downregulated | PKM2(exon 10 inclusion) | [57, 63-66, 133] |
| hnRNPA1                | hnRNPs         | Upregulated| Transcription upregulation | PKM            | PKM1/PKM2 upregulated |                     | [57]      |
| SRSF3                  | SRs            | Upregulated| Protein stability upregulation | MAPK4K        | Map2K4 variants upregulated |                      | [58]      |
| SRSF6                  | SRs            | Upregulated| Transcription upregulation | ZO-1           | ZO-1 E23 skipping variants upregulated | Exon 23 skipping | [59]      |
| SRSF7                  | SRs            | Upregulated| Transcription upregulation | FAS            | FAS-S short isoform of exon 6 skipping | Exon 6 skipping | [60]      |
| SRSF10                 | SRs            | Upregulated| Transcription upregulation | BCLAF1         | BCLAF1-L(exon5a inclusion) upregulated | Exon 5a inclusion | [61]      |
| hnRNPK                 | hnRNPs         | Upregulated| Transcription upregulation | MRPL33         | MRPL33-long isoform upregulated | Exon 3 inclusion | [62]      |
| hnRNPLL                | hnRNPs         | Downregulated| Transcription downregulation | CD44           | CD44v6 (variable exon 6) upregulated | Exon v6 skipping | [96]      |
| PTBP1                  | hnRNPs         | Upregulated| Transcription upregulation | RAC1           | RAC1 isoform b upregulated | Exon 3b inclusion | [64]      |
| PTBP1                  | hnRNPs         | Upregulated| Transcription upregulation | NUMB           | NUMB isoform 1 upregulated | Exon 9 inclusion | [64]      |
| ESRP2                  | Other splicing regulator | Upregulated| Transcription upregulation | ITGA6          | ITGA6A upregulated | Exon 25 skipping | [115]     |
| EFTUD2                 | spliceosome    | Upregulated| Transcription upregulation | MyD88          | MyD88 long isoform upregulated | Full-length (containing intermediate domain) | [52]      |
| EFTUD2                 | spliceosome    | Upregulated| Transcription upregulation | MD-2           | MD-2A long isoform upregulated | Full-length (contain the first 54 bases of exon 3) | [52]      |
| RBM4                   | Other splicing regulator | Downregulated| Transcription downregulation | PTB            | nPTB upregulated | Exon 10 inclusion | [68]      |
| RBM4                   | Other splicing regulator | Downregulated| Transcription downregulation | NOVA1          | NOVA1(-4) upregulated | Exon 4 skipping | [69]      |
| TRA2; SRSF1            | SRs            | Upregulated| Transcription upregulation | BCL2           | BCL2a upregulated | Exon 3 skipping | [77]      |
| PRPF6                  | spliceosome    | Upregulated| Transcription upregulation | ZAK            | ZAK-LF isoform upregulated | Exon 12 inclusion | [134]     |
| hnRNPL                 | hnRNPs         | Upregulated| Transcription upregulation | CEACAM1        | CEACAM1-L upregulated | Exon 7 inclusion | [93]      |
| hnRNPA1                | hnRNPs         | Upregulated| HOXB-A53 peptide binds to hnRNPA1 | PKM            | PKM2 upregulated | Exon 10 inclusion | [72]      |
| hnRNPA1                | hnRNPs         | Phosphorylation of hnRNPA1 upregulated| HOXB-A53 binding to hnRNPA1 | PKM            | PKM2 upregulated | Exon 10 inclusion | [71]      |
| PHF5A                  | spliceosome    | Phosphorylation of PHF5A K29 acetylation | Intracellular retention of PHF5A variant | KDM3A           | Intracellular retention of KDM3A variant | KDM3A | [70]      |
Altered expressions of trans-regulatory factors. Alterations in expression levels of spliceosome components and splicing regulatory proteins are attributed to transcriptional or posttranscriptional regulation, thereby controlling transcriptional or posttranscriptional events that are closely associated with CRC progression (Fig. 2; Table 2). Splicing factor 3b subunit 1 (SF3B1), a core spliceosome component that causes more than 2000 AS events, is associated with most intron retention in CRC cells when it is downregulated [51]. The elongation factor Tu GTP binding domain containing 2 (EFTUD2), a component of the U5 snRNP, is upregulated in colitis-associated cancer. EFTUD2 promotes colitis-associated tumorigenesis by splicing regulation of increased proportion of full-length variant of innate immune signal transduction adaptor (MyD88), since the complete U5 is required for retention of exon 2 [52, 53].

Serine and arginine-rich splicing factor 1 (SRSF1) is a key member of SRs family. It is an oncogenic factor that promotes tumorigenesis by regulating various AS events, such as splicing of Rac Family Small GTPase 1 (RAC1), Tyrosine-protein kinase (SYK), Marker of proliferation Ki-67(MKI67) and heterogeneous nuclear ribonucleoprotein L like (HNRPLL) [51, 54, 55]. In CRC, SRSF1 has been found to be upregulated and is associated with DNA damage and cell cycle progression [50]. Elevated SRSF1 binds 3'SS of DBF4B exon 6 in colon cancer cells to activate it [54, 55]. Other splicing factors, such as SRSF3, SRSF6, SRSF7 and SRSF10 also regulate the splicing of different targets in CRC as oncogenes [56–61].

HnRNPs are primary splicing regulation factors that bind to ESS and ISS elements. Heterogeneous nuclear ribonucleoprotein K (HnRNPK) recognizes exon 3 of mitochondrial ribosomal protein L33 (MRPL33) pre-mRNA. It upregulates MRPL33-L, an exon 3-containing long isoform, through which it exerts its role in maintaining tumorigenic phenotypes of the colon [62].

Other splicing regulatory factors, such as RNA-binding motif protein 4 (RBM4), whose expression is suppressed in cancer, is a tumor suppressor that dysregulates exon 4 skipping of NOVA alternative splicing regulator 1 (NOVA1) and intron 11 retention of PTB [58]. PTBP1 is upregulated by a more stable variant with intron 11 retention and the upregulated PTBP1 is a marker of poor survival outcomes [57, 63]. PTBP1 increases the ratio of the PKM2/PKM1 variant by binding intron 8 of PKM and elevating the PKM2 transcript variant with exon 9 skipping [64–66], thereby enhancing the Warburg effect and promoting tumor progression [67–69].

Posttranslational alterations of trans-regulatory splicing factors. Protein modifications can modulate the splicing ability of trans-regulatory splicing factors (Fig. 2; Table 2). PHD finger protein 5A (PHF5A), a component of U2 snRNPs complex, can be acetylated at lysine 29 by p300 to strengthen interactions among components of U2 snRNPs during colorectal tumorigenesis. The tight complex reduces the retention of intron 3 variant of KDM3A, which triggers the degradation of abnormal mRNAs with early stop codons [70]. Additionally, PHF5A-K29 acetylation is a poor prognostic marker for 3-year overall survival rate [70]. Phosphorylation of the hnRNP A1 Ser6 site by the S6K2 enzyme facilitates the binding of hnRNP A1 to the splicing site of the PKM gene to enhance the generation of PKM2 variants in CRC [71].

Protein interactions between splicing factors regulate splicing by blocking RNA-protein or spliceosome-protein interactions. The HOXB-AS3 peptide competitively binds arginine residues in the RGG motif of hnRNP A1, a splicing regulatory factor that promotes PKM2 variant by flanking 5'SS of exon 9, and thereby excluding exon 9. In CRC cells, HOXB-AS3 has been found to be downregulated, and subsequently, causes PKM2 upregulation that leads to metabolic disorders by antagonizing hnRNP A1 recognition of PKM exon 9 [72].

ALTERNATIVE SPLICING IN CRC PROGRESSION

AS is involved in CRC progression and it plays a key role in multiple malignant hallmark, including sustaining proliferation, inhibiting apoptosis, angiogenesis, aberrant metabolism, invasion and metastasis. We reviewed the splicing variants that are strongly associated with the malignant hallmarks of CRC, and highlighted the variants with clinical relevance (Fig. 3A–E; Supplementary Table 1). And some gene variants in CRC have several malignant functions (Supplementary Table 1) are discussed with their main malignant function. For example, PKM2 variants promote proliferation and inhibit apoptosis, the CD44 v4-v10 variant promotes proliferation, the CD44 v6 variant promotes invasion, the CD44 v9 variant inhibits invasion while the CD44 s variant inhibits proliferation. PKM variants are majorly involved in proliferation while CD44 variants are involved in both proliferation and invasion.

Sustaining proliferation

Sustaining proliferation is one of the malignant features of CRC cells and tumor growth, which can be promoted through the regulation with additional oncogenic splicing isoforms. The CD44 gene is composed of 20 exons, the first exons 1–5 and the last exons 16–20 are constant exons that encode for the N-terminal and C-terminal regions of CD44, respectively. Middle variable exons, respectively abbreviated as exons v1–v10, can be alternatively spliced and translated into different isoforms [73]. Elevated expression of the CD44 v4-10 isoform, which comprises constant and v4-v10 exons, can respond to HGF and Wnt-mediated signals through interactions between the v6 exon and HGF, thereby promoting tumor cell proliferation by maintaining the stemness of cancer stem cells, a feature that is not exhibited by CD44s [74, 75]. This leads to poorer survival rates as was observed in transgenic Cd44v4-10 mice, when compared to CD44s mice [75].

The PKM protein has a switching effect on a specific glyclosis metabolism. Classical splicing variants, PKM1 and PKM2 contain exon 9 or exon 10 (with mutually exclusive exon), respectively, which are under the regulation of hnRNPA1, PTBP1, and SRSF3 [57]. When compared to normal epithelial cells, PKM2 is upregulated by hnRNPA1 overexpression or activation of phosphorylation, which facilitates the binding of hnRNPA1 to the splicing site [57, 71]. Elevated expression of PTBP1 upregulate the PKM2 variant with exon 9 skipping (mentioned in section “Altered expressions of trans-regulatory factors”) [64–66]. Elevated levels of PKM2 promote aberrant metabolism by increasing glycolysis and lactate generation rather than the TCA cycle regardless of oxygen availability, which in turn, accelerates cell proliferation and colon cancer progression [72]. Clinically, univariate and multivariate Cox regression analyses revealed that the expression of both PTBP1 and PKM2 is a significant risk factor for the overall survival of patients with CRC [57, 63, 76].

A full-length variant containing DBF4B exon 6, which has been found to be upregulated in tumors, binds SRSF1 to recognize the 3'SS of DBF4B. Both DBF4B full-length (DBF4B-FL) variant and SRSF1 promote tumor cell proliferation and tumor growth while the DBF4B-short (DBF4B-S) variant does not exhibit a similar function. Moreover, patients with a low DBF4B FL/S ratios have significantly longer median survival outcomes than patients with increased DBF4B FL/S expression ratios [54]. Figure 3A shows some of the proliferation-related gene variants, including HNF4a [47, 48], TRA2B [77], and ID1 [78] with a detailed description in Supplementary Table 1.
Apoptosis
A typical characteristic of malignant tumors is evasion of apoptosis, which is responsible for tumor formation and maintenance. The full-length Fas cell surface death receptor (FAS) protein, also referred to as CD95, is located on the cytomembrane as a receptor. It initiates a cascade of events that eventually lead to programmed cell death. Exon 6 of Fas encodes a transmembrane domain, but skipping of the exon through regulation of SRSF7 splicing produces an mRNA encoding a soluble Fas isoform called Fas-short. SRSF7 is upregulated in CRC cells and it increases the ratio of Fas-short variant, resulting in the loss of function of apoptosis induction.

Fig. 3 Alternative splicing is associated with tumor hallmarks. Five common tumor hallmarks related to alternative splicing include proliferation, invasion and migration, apoptosis, angiogenesis, and drug resistance. The figure shows the hallmarks and the associated genes. A The representative gene and their splicing variants show different functions in cell proliferation. B The representative gene and their splicing variants show different functions in cell apoptosis. C The representative gene and their splicing variants show different functions in angiogenesis. D The representative gene and their variants show different functions in invasion and metastasis. E The representative gene and their splicing variants show different functions in drug resistance. More details about the mechanism of splicing and clinical application are listed in Supplementary Table 1.
thereby exhibiting the inverse feature of the Fas full-length variant [60, 79].

BCL2 Like 1 (BCL2L1), a member of BCL2 Apoptosis Regulator (BCL2) family, is spliced into two isoforms when regulated by hnRNPA2B1 [80]. The BCL-xI isoform of BCL2L1 is 233 amino acids in length and exhibits anti-apoptotic effects, while BCL-xs, which lacks 63 amino acids in exon 2 compared to BCL-xI, is pro-apoptotic [81]. The aberrance of hnRNPA2B1 can result in a switch in the BCL2L1 gene from BCL-xI to BCL-xs in CRC [80]. In addition, BCL2 Associated X (BAX), another key member of the BCL2 family, has been found to have a pro-apoptotic variant (BaxΔ2) with exon 2 skipping. BaxΔ2 triggers apoptosis through a non-mitochondrial pathway, while the Baxα variant promotes mitochondria-dependent apoptosis [82, 83].

MAPK interacting serine/threonine kinase 2 (MNK2) can be spliced by SRSF1 to generate two types of isoforms, MNK2a and MNK2b. MNK2a comprises exons 14a, whereas MNK2b lacks exons 14a. In CRC cells, an imbalance exists between the two isoforms because due to elevated SRSF1 expression, MNK2b is dominant while the MNK2a isoform, which has a MAPK-binding domain, is downregulated, thereby promoting cell growth and reducing cell apoptosis by inhibiting the p38α-MAPK signaling pathway [84].

**Angiogenesis**

The clinical outcome of patients with CRC is strongly correlated with angiogenesis, which is stimulated by the vascular endothelial growth factor-A (VEGF-A) [85]. There are 7 major types of AS isoforms of VEGF (angiogenic VEGF-xoa and antiangiogenic VEGF-xobx) generated by exon skipping in CRC [85–87]. The most studied isoforms are VEGF165a and VEGF165b, which are regulated by SRSF6 and exhibit reversed functions in angiogenesis. VEGF165a is upregulated in CRC and promotes angiogenesis, vessel maturation and cell migration [69]. However, VEGF165b is antiangiogenic and most studies have revealed that it is a favorable prognostic factor in patients with CRC, except for a study by Kotoula that revealed that VEGF165b was associated with poor prognosis in stage II and stage III sporadic CRC compared to VEGF165a [59, 92, 97, 98]. The VEGF165b variant promotes mitochondria-dependent apoptosis [82, 83].

MAPK interacting serine/threonine kinase 2 (MNK2) can be spliced by SRSF1 to generate two types of isoforms, MNK2a and MNK2b. MNK2a comprises exons 14a, whereas MNK2b lacks exons 14a. In CRC cells, an imbalance exists between the two isoforms because due to elevated SRSF1 expression, MNK2b is dominant while the MNK2a isoform, which has a MAPK-binding domain, is downregulated, thereby promoting cell growth and reducing cell apoptosis by inhibiting the p38α-MAPK signaling pathway [84].

**Invasion and metastasis**

Antigen cell adhesion molecule 1 (CEACAM1) is a member of the carcinoembryonic antigen (CEA) family that function as an intercellular adhesion molecule that influence the recurrence of colorectal liver metastasis after hepatectomy [92, 93]. AS of exon 7 by hnRNPL generates two variants, CEACAM1-long and CEACAM1-short (without exon 7). In invasive tumor cells, there is a high proportion of the CEACAM1-short variant, which promotes migration, invasion and proliferation, functions which are not performed by CEACAM1-long [94, 95]. The high expression of CEACAM1-S enhances tumor-initiating of CRC in a metastasis induction model and is negatively correlated with five-year recurrence-free survival rates, and overall survival rates of patients with CRC [92]. Furthermore, CD44 v6 is another CD44 splicing variant, which contains v6 exons by HNRNPLL splicing regulation, is highly expressed in CRC [96]. CD44 v6 isoform can enhance EMT progress, cell motility and invasion as an intercellular communicator when located on the cytomembrane or exosome [97, 98]. The high levels of CD44v6 can be used as a marker for predicting poor prognosis in stage II and stage III sporadic CRC compared with CD44s. In addition, high expression of CD44v6 is significantly correlated with poor histological differentiation, deeper tumor invasion, increased lymph node metastases, angiolympathic invasion, and advanced pathological TNM (Tumor, Node, Metastasis) staging in the clinical-pathological analysis of CRC [99].

**Drug resistance**

AS has been reported to influence the development of drug resistance in malignant cancer cells. BCL-2-associated X (BAX) is an apoptosis regulator that can be spliced into a unique Bax isoform (BaxΔ2) in colon cancer cells because of BAX microsatellite G7/G7 alleles [83, 100]. BaxΔ2-positive cells can recruit caspase-8 into the proximity for activation, and subsequently activate caspase-3 and apoptosis independent of the mitochondrial pathway [83]. Overexpression of BaxΔ2 can enhance sensitivity of tumor cells to proteasome inhibitors, such as bortezomib and carfilzomib, which could be a novel chemotherapeutic target for cancer treatment [101].

Bevacizumab, normally recommended for the treatment of patients with metastatic CRC patients with metastasis, targets VEGF signaling. Bevacizumab response is associated with AS of VEGF isoforms. For example, the VEGFA145b isoform may predict resistance to bevacizumab in patients with left-sided primary CRC [85]. Results of immunohistochemical analyses of CRC have suggested that plasma VEGF-Axxb levels could be an effective biomarker of response to bevacizumab [90, 102]. Previous studies also revealed that xenograft mice with a high ratio of VEGF165b isoform were more sensitive to bevacizumab treatment and hence had tumors with smaller volumes [89].

**POTENTIAL TUMOR DIAGNOSIS AND TREATMENT TARGETS FOR CRC**

Ablative splicing mechanisms and the corresponding products are potential diagnostic markers and predictors of the survival of the patients with CRC. The RAS family is significant for CRC progression with several alternative splice variants, which are associated with several clinicopathological features of CRC [103]. K-RA54A, retaining extra exon 4A when compared with K-RA54B, is associated with superior 5-year overall survival in KRAS wild-type subgroup and clinicopathological features of left colon, adenocarcinoma subtype. Nonetheless, KRAS54B overexpression is significantly associated with larger tumor size and inversely correlated with p27kip1 protein [104–106]. Beyond that, some other variants, such as Q0-1 exon23 skipping isoform, CD44v6, CEACAM1-Short isoform, Δ133p53B with inr04 retention were negative survival markers in CRC [59, 92, 97, 98]. The VEGFA 165b variant promotes mitochondria-dependent apoptosis in CRC [85, 88–90](Supplementary Table 1).

Additionally, the complex mechanism of AS can provide novel therapeutic targets for patients with CRC. The direct therapeutic strategies of splicing alterations can be divided into 3 categories based on splicing mechanism: (1) strategies targeting cis-elements of splicing, (2) strategies targeting trans-regulatory factors of splicing, including the spliceosome complex and splicing regulation factors, especially the spliceosome complex and splicing regulation factors, and (3) strategies targeting splicing variants and the downstream mechanisms. Complex splicing mechanisms can be used to develop multiple target therapies for patients with CRC (Fig. 4). The common drugs for splicing intervention are antisense oligonucleotides (ASOs) that target base sequences and small molecules altering the activities of splicing regulatory factors. Agents are listed in Table 3 with experimental evidence to confirm as treatment targets by targeting AS.

**Therapeutic approaches of antisense oligonucleotides**

A more direct method of regulating a specific splicing event is by exploring splice-switching oligonucleotides (SSOs), which belong to ASOs with splicing intervention functions. Briefly, SSOs typically consist of sequences of ~15–30 nucleotides that are chemically modified to avoid degradation by exonucleases, and bind to a
Table 3 for detail. Inhibitors targeting oncogenic variants or signaling are shown in the diagram. See text and Table 3 for detail.

Some special splicing variants related to carcinogenesis are effect targets for inhibitor and colorectal treatment. Inhibitors targeting oncogenic variants or signaling are shown in the diagram. See text and Table 3 for detail.

Therapeutic approaches of small molecule inhibitors

Small molecule drugs that exhibit potent anticancer activity have been developed by targeting splicing factors to modulate their activities or products that promote tumor growth by splicing. Nevertheless, small molecule drugs could potentially inhibit splicing but they lack specificity when compared with SSOs therapy. Small molecule inhibitors targeting AS are listed in Fig. 4B, C and Table 3.

Targeting of core spliceosome complex and regulatory proteins.

Application of indacaterol, which is an inhibitor that targets the functional RRM2 domain of SRSF6, can inhibit SRSF6 and binding to exon23 of tight junction protein 1 (ZO-1) in splicing regulation, which effectively reduces CRC progression [59]. SF3B1 is a crucial spliceosome component that participates in the splicing and synthesis of mature mRNA. FR901464 is a small molecule inhibitor that binds to SF3B1 and can destabilize the recruitment of snRNP U2 to SF3B1, which ultimately decreases cell proliferation and tumor growth [114]. Moreover, certain molecules that target splicing regulation factors exhibit anti-cancer activity in CRC. For example, 10058-F4 (MYC inhibitor) suppresses the expression of epithelial splicing regulatory protein 2 (ESRP2) and SM08502 (CLKs inhibitor) decreases phosphorylation of SRSFs [115, 116].

Targeting of splicing variants or translation products or downstream targets.

Some drugs have been developed to specifically target splicing variants or their translation isoforms to inhibit tumor progression, like Prodigiosin (targeting ΔNp73) [117], Nilotinib (targeting ZAK) [118], SB21673 (targeting ITGA6A) [115], etc. (Refer to Table 3 for detail).

The BTK gene can be developed as a multi-target agent because of its complex splicing mechanisms. P65BTK is an oncogenic isoform and is dependent on splicing by p-hnRNPK, which is phosphorylated by signal-regulated protein kinases-1/2 (ERK1/2) and RAS. Not only Ibrutinib and AVL-292 (inhibitors of P65BTK), but also the FTI-277 (inhibitors of p-hnRNPK, targeting RAS) and
| Agents | Splicing gene | Direct targets | Mechanism | Stage of development | Reference |
|--------|---------------|----------------|-----------|----------------------|-----------|
| SSO    | BCLAF1        | 3'SS at the boundary of intron 4 and exon 5a | SSO treatment increase truncated isoform against SR5F010 splicing effect and inhibits cell proliferation. | Preclinical Cell level | [61]      |
| SSO    | PKM           | SSO against exon 10 for PKM | The SSO against exon 10 for PKM gene decreased the mRNA ratio of PKM2/PKM1. | Preclinical Cell level | [59, 71]  |
| SSO    | DVL           | 3'SS of intron 2 of DVL2 | The increasing intron2 retention variant for DVL2 can inhibits cell proliferation whether SETD2 exists or not. | Preclinical Cell level | [46]      |
| SSO (2'-OMe phosphorothioatoion) | HnRNP A1 | Blocking 5' SS of SMN2 exon 7 | The SSOs targeted hnRNP A1 binding sites of SMN exon 7 and then reduced oncogenic exon 7 inclusion variant to inhibit CRC. | Preclinical Cell level | [57, 71, 135] |
| RHPS4, G4 structures | CD133 | The 118 bp upstream and 261 bp downstream of acceptor sites of exons 4 and 7 | RHP54 treatment increase intron3,6 retention variant with early termination of translation, then cause more truncated isoform CD133 and supress cell growth. | Preclinical Cell level Mice level | [121] |
| Prodigiosin | P73 | Upregulated c-Jun, and induced phosphorylation of c-Jun | Prodigiosin induces phosphorylation of c-Jun, which mediates p73 upregulation and ΔNp73 downregulation and then inhibited the growth of xenograft tumors initiation. | Preclinical Cell level Mice level | [117] |
| Ibrutinib (BTK) AVL-292 (BTK) | BTK | BTK kinase inhibitor | The inhibitor of P68BTK oncogenic isoform depends on p-hnRNPK, which is active by ERK1/2 and RAS. | Preclinical Cell level | [119] |
| FTI-277 (RAS) CI-1040 (MEK1/2) | | Inhibitor of hnRNPK phosphorylation | | | |
| Nilotinib (ZAK inhibitor) | ZAK | Inhibitor of ZAK-autophosphorylation and auto-activation | Nilotinib suppresses pro-tumoral reaction cascades of ZAKs, which are key factors in cancer cell migration. | Preclinical Cell level | [118] |
| Bay 11-7082 (NF-κB inhibitor) | TXL2 | NF-κB(downstream of oncogenic TXL-2b variants) | TXL-2b contributes to resistance against vincristine and induces apoptosis by activating NF-κB signaling and blocking the downstream. | Preclinical Cell level | [120] |
| SSO (locked nucleic acid, LNA) | Aurora-A | Target exon 2-containing Aurora-A 5' UTR | SSO targets the carcinogenic exon 2-containing Aurora-A mRNA isoforms can inhibit tumor growth. | Preclinical Cell level Mice level | [136] |
| SSO (antisense morpholino oligomer) | VEGFR | Against 5'SS of exon13-intron13 junction | SSO is directed against the junction sequence that shifts expression from mVEGFR2 to the antiangiogenic sVEGFR. | Preclinical Cell level | [91] |
| 10058-F4 (MYC inhibitor) | ITGA6 | MYC inhibitor | MYC inhibitor increases the epithelial splicing regulatory protein 2 (ESRP2) and decreases the tumor promoter ITGA6 variant. | Preclinical Cell level Mice level | [115] |
| SB21673 (GSK3β inhibitor) | | | | | |
| SM08502 small molecular inhibitor | DVL2, ERBB2, LRP5, TCF7 | Inhibitor of CLKs | SM08502 inhibits SRSF phosphorylation and disrupts spliceosome activity, which inhibits of Wnt pathway-related gene and expression of splicing regulator. | Preclinical Cell level Mice level Phase 1 clinical trial (NCT03355066) | [116] |
| Agents | Splicing gene | Direct targets | Mechanism | Stage of development | Reference |
|--------|---------------|----------------|-----------|----------------------|-----------|
| FR901464 (Small molecular inhibitor) | KDM3A | Block the kinase activity of HDAC to decrease PHF5A acetylation | Preclinical | [70] |
| KDM3A | SF3B1 | SF3B1 and splicing assembly and tumor growth, inhibits tumor growth | Preclinical | | |
| Pladienolide B | SF3B1 | SF3B1 and splicing assembly and tumor growth | Preclinical | | |
| Indacaterol (SRSF6 inhibitor) | ZO-1 | Binding to RRM2 domain of ZO-1 | | | |
| Y. Chen et al. | | | | | |
| | | | | | |
| SSO Splice Switching Oligonucleotides, 3' SS site, 5' SS site. | CI-1040 (inhibitors of p-hnRNPK, targeting MEK1/2), can suppress tumor progression [119]. The multi-target agents could provide novel strategies that address drug resistance and enhance therapeutic effects. Notably, certain inhibitors targeting downstream of specific splicing products can also be used as potential treatment strategies. Thioredoxin-like protein 2 variant 2 (Txl-2b), a specific isofrom upregulated in CRC by splicing, activates NF-κB signaling and inhibues NF-κB-regulated gene products, but other isoforms do not perform such functions. Treatment with Bay 11-7082 (NF-κB inhibitor) enhances the sensitivity of tumor cells against vincristine and induces apoptosis in vitro, which shows the potential of combining treatment in drug-resistance CRC [120].

**Others therapeutic targets**

Specific aberrant RNA sequences or structures (such as hairpins or G-quadruplexes) can block recruitment of splicing factors to splicing sequences, which could serve as novel therapeutic targets for CRC. Two G4s are detected at 118 bp upstream and 261 bp downstream of the acceptor sites of the exons 4 and 7 of CD133, respectively. As an exogenous mimic of G sequence, RHP54 targets G-quadruplexes (G4s) leading to a marked reduction of CD133 mature transcripts that is counterbalanced by an increase in splicing variants corresponding to enhanced intron retention, which ultimately inhibits tumor progression [121].

**CONCLUSION**

RNA splicing is a molecular event that occurs after the posttranscriptional gene expression processes in invertebrates. A aberrant splicing is associated with the development of diseases, such as cancer. Advances in nucleic acid sequencing and computational biology increase our understanding of the relationship between colorectal cancer and AS [64, 122]. The emergence of single-cell sequencing technology makes it possible to screen out one or several splice variants in tumor cells that are not present in heterogeneous tumor tissues [123]. In addition, it is emerging from previous studies that non-coding RNA splicing has important pathological implications. For example, circular RNAs are by-products of back-splicing of premRNA and regulate biological processes by acting either as sponges of microRNAs (miRNAs) or RNA-binding proteins. Research on the roles of circRNA in CRC is still in its infancy stage and hence further studies are advocated to expose the potential of using circRNA as biomarkers and therapeutic targets [124].

In this review, we summarized findings from research on the role of AS in CRC in the past 5 years and reveal their clinical value. Inaccurate sequences on cis-elements and changes in the transcriptional and posttranslational regulation factors result in aberrant AS or new splicing events. This affects malignant hallmarks such as proliferation, apoptosis, invasion, migration, and drug resistance. AS signature profiles or patterns can be used as disease biomarkers. Some specific splicing variants are associated with tumor grade and prognosis of patients, and can be applied in clinical practice. For instance, KRAS-A and VEGFA 165b variant are superior predictors of overall survival whereas CD44v6, CEACAM1-Short isoform, and Δ133p53β variant are poor predictors of overall survival among patients with CRC [59, 85, 88, 90, 97, 98, 104–106]. SSOS and small molecular drugs that target various aspects of splicing progress or products can suppress tumor progression, some of which have been investigated in phase I clinical trials, such as E7107 and SM08502.

However, the function of AS in the progression of CRC is still poorly understood, at least compared to prostatic cancer or breast cancer. Even so, they offer hope with exposing novel mechanism of low toxicity and new opportunity for the use of SSOS in precision medicine with less off-target effect. Although
SSOs confer some benefits in patients with Duchenne muscular dystrophy (DMD) [125], its role in CRC patients has not been sufficiently explored [126]. It is worth mentioning that the high polarity and charged characteristics of oligonucleotide drugs make them obvious differences between small chemical molecules and monoclonal antibody drugs in terms of drug delivery system, pharmacokinetic properties, and efficacy [110]. Although significant progress has been made, the tumor-specific splicing alterations are not fully characterized and further efforts are needed to comprehensively reveal the regulation splicing of AS events.

REFERENCES

1. Berget SM, Moore C, Sharp PA. Spliced segments at the 5’ terminus of adenovirus 2 late mRNA. Proc Natl Acad Sci USA. 1977;74:3171–5.
2. Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57–74.
3. Vaquero-Garcia J, Barrera A, Gazzara MR, Gonzalez-Vallinas J, Lahens NF, Hoganesch JB, et al. A new view of transcriptome complexity and regulation through the lens of local splicing variations. Elife. 2016;5:e11752.
4. Aebersold R, Mann M. Mass-spectrometric exploration of proteome structure and function. Nature. 2016;537:347–55.
5. Scotti MM, Swanson MS. RNA mis-splicing in disease. Nat Rev Genet. 2016;17:19–32.
6. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
7. Capon DJ, Seeburg PH, Hayflick J, Edman U, Levinson AD, et al. Activation of K-ras2 gene in human colon and lung carcinomas by two different point mutations. Nature. 1983;304:557–13.
8. Amirkhal R, Naderi-Meshkin H, Shah JS, Dunne PD, Schmitz U. The intricate interplay between epigenetic events, alternative splicing and noncoding RNA deregulation in colorectal cancer. Cells. 2019;8:929–52.
9. Miura K, Fujibuchi W, Unno M. Splice isoforms as therapeutic targets for colorectal cancer. Carcinogenesis. 2012;33:3111–9.
10. Matos P, Jordan P. Targeting colon cancers with mutated BRAF and microsatellite instability. Adv Exp Med Biol. 2018;110:7–21.
11. Canavesse M, Ngo DT, Maddern GJ, Hardingham JE, Price TJ, Hauben E. Biology and therapeutic implications of VEGF-A splice isoforms and single-nucleotide polymorphisms in colorectal cancer. Int J Cancer. 2017;140:2183–91.
12. Lee Y, Río DC. Mechanisms and regulation of alternative pre-mRNA splicing. Annu Rev Biochem. 2015;84:291–323.
13. Ule J, Blencowe BJ. Alternative splicing regulatory networks: functions, mechanisms, and evolution. Mol Cell. 2019;76:329–45.
14. Fica SM, Tuttle N, Novak T, Li NS, Lu J, Koohdathingal P, et al. RNA catalyses nuclear pre-mRNA splicing. Nature. 2013;503:229–34.
15. Bertram K, Agafonov DE, Dybkov O, Haselbach D, Leelaram MN, Will CL, et al. Cryo-EM structure of a pre-catalytic spliceosome. Nature. 2017;546:470–6.
16. Plaschka C, Lin PC, Nagal K. Structure of a pre-catalytic spliceosome. Nature. 2017;542:318–20.
17. Gueroussov S, Weatheritt RJ, O’Hannon D, Lin ZY, Narula A, Gingeras RC, et al. Regulatory expansion in mammals of multivalent hnRNP assemblies that globally control alternative splicing. Cell. 2017;170:701–73 e1711.
18. Plaschka C, Lin PC, Nagal K. Structure of a pre-catalytic spliceosome. Nature. 2017;546:617–21.
19. Gueroussov S, Weatherritt RJ, O’Hannon D, Lin ZY, Narula A, Gingeras RC, et al. Regulatory expansion in mammals of multivalent hnrNP assembles that globally control alternative splicing. Cell. 2017;170:324–39 e323.
20. Feng H, Bao S, Rahman MA, Weyn-Vanhentenryck ML, Khan W, Jeng J, et al. Modeling RNA-binding protein specificity in vivo by precisely registering protein-RNA crosslink sites. Mol Cell. 2019;74:1189–204 e1186.
21. Ferrarese R, Harsh GR, Yadav AK, Bug E, Maticzka D, Reichardt W, et al. Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression. J Clin Investigation. 2014;124:2861–76.
22. Krishnath R, Blanco SR, Whicheaver ML, Abelson J, Guthrie C, Walter NG. Biased Brownian ratcheting leads to pre-mRNA remodeling and capture prior to first-step splicing. Nat Struct Mol Biol. 2013;20:1450–7.
23. Goldammer G, Neumann A, Strauch M, Muller-McNicoll M, Heyd F, Preussner M. Characterization of cis-acting elements that control oscillating alternative splicing. RNA Biol. 2018;15:1081–92.
24. Akerman M, Fregoso OJ, Das S, Ruse C, Jensen MA, Pappin DJ, et al. Differential connectivity of splicing activators and repressors to the human spliceosome. Genome Biol. 2015;16:119.
25. Zhang X, Yan C, Zhan X, Li L, Lei J, Shi Y. Structure of the human activated spliceosome in three conformational states. Cell Res. 2018;28:307–22.
26. Zhang X, Yan C, Hang J, Finci U, Lei J, Shi Y. An atomic structure of the human spliceosome. Cell. 2017;169:918–29 e914.
50. Lopez-Sanchez LM, Jimenez-Izquierdo R, Penarando J, Mena R, Guil-Luna S, Toledano M, et al. SWATH-based proteomics reveals processes associated with immune evasion and metastasis in poor prognosis colorectal tumors. J Cell Mol Med. 2019;23:8219–32.

51. Komor MA, Pham TV, Hiemstra AC, Piersma SR, Bolijn AS, Schellfforst H, et al. Identification of differentially expressed splice variants by the proteogenomics approach, in Cell Proteomics. 2017;16:1850–63.

52. Lu Z, Wang Z, Luo L, Chen Y, Han G, Wang R, et al. Spliceosome protein Efd2 promotes cell-context-associated tumorigenesis by modulating inflammatory response of macrophage. Mucosal Immunol. 2019;12:1164–73.

53. De Arras L, Laws R, Leach SM, Pontis K, Freedman JH, Schwartz DA, et al. Comparative genomics RNAi screen identifies Efd2 as a novel regulator of innate immunity. Genomics. 2019;119:408–20.

54. Chen L, Luo C, Shen L, Liu Y, Wang Q, Zhang C, et al. SRSF1 prevents DNA damage and promotes tumorigenesis through regulation of DBF4B Pre-mRNA splicing. Cell Rep. 2017;21:3406–13.

55. Chen YT, Chang IY, Liu H, Ma CP, Kuo YP, Shih CT, et al. Tumor-associated intronic editing of hnRNP L generates a novel splicing variant linked to cell proliferation. J Biol Chem. 2018;293:10158–71.

56. Park SK, Jeong S. SRSF3 repression the expression of PDCD4 protein by coordinated regulation of alternative splicing, export and translation. Biochem Biophys Res Commun. 2016;470:431–8.

57. Kuranaga Y, Sugito N, Shinohora H, Tsujino T, Taniguchi K, Komura K, et al. Intronic editing of HNRPLL generates a novel splicing variant linked to cell context-dependent manner. Oncol Lett. 2017;14:7323.

58. Lin JC, Lee YC, Tan TH, Liang YC, Chuang HC, Fan YC, et al. RBM4-SRSF3- MAPK4 splicing cascade modulates the metastatic signature of colorectal cancer cell. Biochem Biophys Acta Mol Cell Res. 2018;1865:259–72.

59. Wang L, Wu Y, Shen E, Sun W, Liu Y, Kong J, et al. SRSF6-regulated alternative splicing that promotes tumour progression offers a therapy target for colorectal cancer. Gut. 2019;68:118–29.

60. Fu Y, Wang Y. SRSF7 knockdown promotes apoptosis of colon and lung cancer cells. Oncol Lett. 2018;15:5455–62.

61. Zhou X, Li X, Cheng Y, Wu W, Xie Z, Xi Q, et al. BCLAF1 and its splicing regulator hnRNPK are required for mitochondria function and implicated in tumor progression. Oncogene. 2018;37:86–94.

62. Taniguchi K, Sakai M, Sugito N, Kumazaki M, Shinohora H, Yamada N, et al. PTBP1-associated microRNA-1 and -133b suppress the Warburg effect in colorectal cancer. Oncotarget. 2016;7:18940–92.

63. Hollander D, Donyo M, Atlas N, Mekahel K, Melamed Z, Yannai S, et al. A network-based analysis of colon cancer splicing changes reveals a tumorigenesis-favoring regulatory pathway emanating from ELK1. Genome Res. 2016;26:541–53.

64. Cheng C, Xie Z, Li Y, Wang J, Qin C, Zhang Y. PTBP1 knockdown overcomes the resistance to vincristine and oxaliplatin in drug-resistant colon cancer cells through regulation of glycosylation. Biochem Pharmacother. 2018;108:194–200.

65. Kumazaki M, Shinohora H, Taniguchi K, Takai T, Kuranaga Y, Sugito N, et al. Perturbation of the Warburg effect increases the sensitivity of cancer cells to TRAIL-induced cell death. Exp Cell Res. 2016;347:133–42.

66. Markus MA, Yang YH, Morris BJ. Transcriptome-wide targets of alternative splicing by RBM4 and possible role in cancer. Genomics. 2016;107:138–44.

67. Liang YC, Lin WC, Lin YJ, Lin JC. The impact of RNA binding motif protein 4-regulated splicing cascade on modulating the carcinogenic signature of colorectal cancer cells. Sci Rep. 2017;7:44204.

68. Wang Z, Yang X, Liu C, Li X, Zhang B, Wang B, et al. Acetylation of PHF5A promotes tumorigenesis of colorectal cancer cells. Oncol Lett. 2017;14:7323–31.

69. Huang JZ, Chen M, Chen G, Xue S, Zhang B, et al. Peptide encoded by a putative IncRNA Hoxb13-A5S suppresses colorectal cancer growth. Mol Cell. 2019;74:1250–63.e1256.

70. Schmitt M, Metzger G, Grad D, Davidson G, Orian Rousseau V. CD44 functions in Wnt signaling by regulating LRPS localization and activation. Cell Death Differ. 2015;22:677–89.

71. Joosten SPJ, Zielstra J, van Andel H, Mijnals RC, Zaunbrecher J, Duivenvoorden AAM, et al. MET signaling mediates intestinal crypt-villus development, regeneration, and adenoma formation and is promoted by stem cell CD44 isoforms. Gastroenterology. 2017;153:1040–53.e1044.

72. Zielstra J, Joosten SPJ, van Andel H, Tolg C, Berns A, Snoek M, et al. Stem cell CD44v isoforms promote intestinal cancer formation in Apc(min) mice down-stream of Wnt signaling. Oncogene. 2014;33:685–70.

73. Cui R, Shi XY. Expression of pyruvate kinase M2 in human colorectal cancer and its prognostic value. Int J Exp Pathol. 2015;91:139–93.

74. Kuwano Y, Nishida K, Kajita K, Satake Y, Akaie Y, Fujita K, et al. Transformer 2beta and miR-204 regulate apoptosis through competitive binding to 3’ UTR of BCL2 mRNA. Cell Death Differ. 2015;22:815–25.

75. Manrique I, Nguema P, Bleau AM, Nistal-Villan E, Lopez I, Villalba M, et al. The inhibitor of differentiation isoform id1D, generated by alternative splicing, maintains cell quiescence and confers renewal and cancer stem cell-like properties. Cancer Lett. 2015;356:899–909.

76. Jakubauskiene E, Peciuliene I, Vilys L, Mocevicius P, Kanopka A. Gastrointestinal tract tumors and cell lines possess different splicing factor expression and tumor associated mRNA isoform formation profiles. Cancer Biomark. 2015;15:575–81.

77. Makhaloula TJ, Mibe M, Yacoub-Ussman K, Hendren A, Haigh DB, Blackley Z, et al. Apoptosis in cancer cells is induced by alternative splicing of hnrNPA2/B1 through splicing of Bcl-x, a mechanism that can be stimulated by an extract of the South African medicinal plant, cotedylon orbiculata. Front Oncol. 2020;10:547392.

78. Sillars-Hardebol AH, Carvalho B, Belien JA, de Wit M, Delis-van Diemen PM, Tijssen M, et al. BCL2L1 has a functional role in colorectal cancer and its protein expression is associated with chromosome 20q gain. J Pathol. 2012;226:442–50.

79. Manas A, Yao Q, Davis A, Basheer B, Beatty E, Zhang H, et al. Immunohistochemical detection of the pro-apoptotic Bax2 protein in human tissues. Histochern Cell Biol. 2020;154:41–53.

80. Zhang H, Lin Y, Manas A, Zhao Y, Denning MF, Ma L, et al. BaxDelta2 promotes apoptosis through caspase-8 activation in microsatellite-unstable colon cancer. Mol Cancer Res. 2014;12:1225–32.

81. Maimon A, Mogilevsky M, Shilo A, Golan-Gerstl R, Obiedat A, Ben-Hur V, et al. Mnk2 alternative splicing modulates the p38-MAPK pathway and impacts radiation induced transformation. Cell Rep. 2014;7:501–13.

82. Pentheroudakis G, Mavroeldis E, Papadopoulos K, Kolou G, Bainia C, Chatzopoulou K, et al. Angiogenic and antiangiogenic VEGFA splice variants in colorectal cancer: prospective retrospective cohort study in patients treated with irinotecan-based chemotherapy and bevacizumab. Clin Colorectal Cancer. 2019;18:e370–e384.

83. Zeyszeva YY, Elliott VA, Rychhau P, Mustain WC, Kim JT, Valentino J, et al. Cancer cell-associated fatty acid synthase activates endothelial cells and promotes angiogenesis in colorectal cancer. Cancer Res. 2014;75:1341–51.

84. Kazemi M, Carrer A, Moimas S, Zandonà L, Bussani R, Casagranda B, et al. VEGF121 and VEGF165 differentially promote vessel maturation and tumor growth in mice and humans. Cancer Gene Ther. 2016;23:125–32.

85. Stagg BC, Uehara H, Lambert N, Rai R, Gupta L, Radmall B, et al. Morpholino-mediated isof ormulation by the proteogenomic pipeline splicify. Mol Cell Proteom. 2017;16:1850–62.

86. Stagg BC, Uehara H, Lambert N, Rai R, Gupta L, Radmall B, et al. Morpholino-mediated isoformulation by the proteogenomic pipeline splicify. Mol Cell Proteom. 2017;16:1850–62.
100. Xu W, Jing L, Wang Q, Lin CC, Chen X, Diao J, et al. Bax-PGAM5L-Drp1 complex is required for intrinsic apoptosis execution. Oncotarget. 2015;6:3909–3916.

101. Manas A, Chen W, Nelson A, Yao Q, Xiang J. BaxDelta2 sensitizes colorectal cancer cells to proapoptotic inhibitor-induced cell death. Biochem Biophys Res Commun. 2018;496:18–24.

102. Bunni JS-FG, Stevenson K, Oltean S, Salmon A, Harper SJ, Carter JG, et al. Circulating levels of anti-angiogenic VEGF-A (isomeric VEGF-Axxob) in colorectal cancer patients predicts tumour VEGF-A ratios. Am J Cancer Res. 2015;5:2083–2093.

103. Nussinov R, Tsai CJ, Chakrabarti M, Jang H. A new view of Ras isoforms in colorectal cancer. Toxicol Appl Pharm. 2019;364:55–63.

104. Hammond SM, Aartsma-Rus A, Alves S, Borgos SE, Buijsen RAM, Collin RWJ, et al. Alternative splicing of the vitamin D receptor modulates target gene expression and promotes ligand-independent functions. Toxicol Apppl Pharm. 2019;364:55–63.

105. Abubaker J, Bavi P, Al-Haqawi W, Sultana M, Al-Haribi S, Al-Sanea N, et al. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J Pathol. 2009;219:435–442.

106. Eliertsen IA, Sveen A, Strome JM, Skothiem R, Nesbakken A, Lothe RA. Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancer. Int J Cancer. 2019;144:841–7.

107. Geary RS, Norris D, Yu R, Bennett CF. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev. 2015;87:46–51.

108. Xue XY, Mao XG, Zhou Y, Chen Z, Hu Y, Hou Z, et al. Advances in the delivery of antisense oligonucleotides for combating bacterial infectious diseases. Nat Medicine. 2018;14:745–58.

109. Annalora AJ, Jozic M, Marcus CB, Iverson PL. Alternative splicing of the vitamin D receptor modulates target gene expression and promotes ligand-independent functions. Toxicol Appl Pharm. 2019;364:55–63.

110. Hammond SM, Aartsma-Rus A, Alves S, Borgos SE, Buijsen RAM, Collin RWJ, et al. Delivery of oligonucleotide-based therapeutics: challenges and opportunities. EMBO Mol Med. 2021;13:e12343.

111. David A, Sriangalingam AM, Methrell LA, Khoo B, Clark AJ. Repair of aberrant splicing in growth hormone receptor by antisense oligonucleotides targeting the cdc42 and splice variant CDA44v6 as molecular imaging targets. Theranostics. 2017;7:482–92.

112. Wang Z, von Au A, Schnolzer M, Hackert T, Zoller M. CD44v6-competent colorectal cancer cells respond to anti-CD44v6 peptides and anti-CD44v6 monoclonal antibodies. Int J Cancer. 2019;144:839–41.

113. Liu W, Zhang X, Singh M, Khouri AM, Donahue SH. Alternative splicing analysis reveals dominance of single transcript variant. Genomics. 2020;112:2418–25.

114. Yamamoto T, Kubo S, Yano A, Kominato T, Tanaka S, Ikeda M, et al. Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy type 1 splicing correction in patient-derived cells and mice. J Clin Invest. 2019;129:4739–4753.

115. Grassilli E, Pisano F, Cialdella A, Bonomo S, Missaglia C, Cerrito MG, et al. A novel splice-sensor system for investigating alternative splicing events in colorectal cancer development. Cell Death and Disease. 2021;12:752.

ACKNOWLEDGEMENTS

This work was supported by the National Natural Science Foundation of China (81752437 and 81702042 to XC, 81702442 to ZL), the Natural Science Foundation of Jiangsu province [BK20170623 to ZL, BK202004179 to GF], the China Postdoctoral Science Foundation [2020M670092X to ZL], the Postdoctoral Science Found of Jiangsu province [2018K0908 to ZL].

AUTHOR CONTRIBUTIONS

XC, ZL, and GF provided the idea of the article. YC, MH, and XL wrote the article. YH, CL, JZ, SS, LJ, and XM helped with the experimental work. XC, ZL, and GF provided the idea of the article. YC, MH, and XL wrote the article. YH, CL, JZ, SS, LJ, and XM helped with the experimental work. All authors have reviewed the manuscript and approved the final manuscript.

COMPETING INTERESTS

The authors declare no competing interests.
ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41419-021-04031-w.

Correspondence and requests for materials should be addressed to G.F., Z.L. or X.C.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Consent for publication All authors have agreed on the contents of the manuscript.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021